
This dose escalation study aimed to determine the recommended doses, toxicity and zzso of zzso and zzso given on days 1 and 8 every 21 zzso This schedule may maximize dose intensity of both drugs with acceptable or reduced zzso 

zzso patients had solid zzso no more than two prior courses of chemotherapy, zzso performance status zzso zzso zzso or zzso zzso grade 1 and adequate organ zzso zzso escalation commenced at zzso 40 zzso and zzso 750 zzso both given on days 1 and 8 every 21 days, and reached zzso 80 zzso and zzso 1,500 zzso The two highest dose levels were each expanded to six patients to gain additional toxicity zzso 

There were no dose limiting zzso related to treatment and an zzso was not zzso Five patients zzso had grade 3 zzso without associated infection, and seven patients zzso had grade 3/4 zzso zzso was mild and no worse than grade zzso Two patients with zzso zzso had partial responses and 11 patients zzso had disease zzso No zzso interaction between zzso and zzso was zzso zzso intensity was zzso at level 4 zzso 70 zzso and zzso 1,250 zzso 

This schedule allows zzso and zzso to be delivered at the full dose intensity of each drug with excellent zzso and predictable zzso The recommended doses for phase II studies are zzso 70 zzso and zzso 1,250 zzso on days 1 and 8 every 21 zzso 

